AIM ImmunoTech Inc. (AIM) research

AIM ImmunoTech Inc.

Sector: Healthcare
Industry: Biotechnology
Last price: $0.18
As of: 2026-10-02

AIM ImmunoTech Inc. (AIM): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.

As of 2026-09-14, the latest of: this ticker's 13F holdings load, its latest SEC filing date, and its latest signal other than 13F-derived signals. Source: SEC EDGAR filings for AIM. Method and limitations.

COMPANY DOSSIER

See the full AIM dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for AIM on one page. Preview it with sample data, then open it live with a free account.

Preview the AIM dossier

Active signals for AIM

mediumEARNINGS_MISS2026-08-10
Q2-2026: Missed consensus by 150.4%, EPS $-0.43 vs $-0.1717 estimate
All 2026-08-10 signals →
mediumEARNINGS_BEAT2026-06-16
Q2-2025: Beat consensus by 54.5% - EPS $-3.67632 vs $-8.0719 estimate
All 2026-06-16 signals →
mediumEARNINGS_MISS2026-06-16
Q3-2025: Missed consensus by 59.4% - EPS $-1.56843 vs $-0.9838 estimate
All 2026-06-16 signals →
mediumEARNINGS_MISS2026-06-16
Q4-2025: Missed consensus by 47.9% - EPS $-1.44 vs $-0.9737 estimate
All 2026-06-16 signals →
mediumEARNINGS_MISS2026-06-16
Q1-2026: Missed consensus by 52.5% - EPS $-0.57 vs $-0.3737 estimate
All 2026-06-16 signals →

FREE, NO ACCOUNT

Every signal on AIM, as it fires

New filings, 13F moves and cross asset signals on AIM land in the record first.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.

Recent SEC filings, AIM

8-K2026-09-14
SEC EDGAR ↗
8-K2026-09-10
SEC EDGAR ↗
8-K2026-09-04
SEC EDGAR ↗
8-K2026-08-11
SEC EDGAR ↗
8-K2026-08-10
SEC EDGAR ↗
10-Q2026-08-07
SEC EDGAR ↗
8-K2026-08-06
SEC EDGAR ↗
8-K2026-08-05
SEC EDGAR ↗
8-K2026-07-16
SEC EDGAR ↗
8-K2026-06-15
SEC EDGAR ↗

AIM against its peers

AIM's operating margin of -13254.5% ranks in the 12th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-08-31 and 2026-04-30.

Metric	AIM	Peer median	Percentile	n
Revenue FY	88000 USD	2.6M USD	30	14
Gross margin	n/a	63.4%	n/a	7
Operating margin	-13254.5%	-484.3%	13	11
Net margin	-15861.4%	-433.7%	13	11
Return on equity	n/a	-205.3%	n/a	19

Peers (20): OSRH, CLGN, SKYE, CNSP, LEXX, IMNN, ENSC, BOLT, CURX, CELZ, XCUR, CSCIF, RVPH, ALZN, LGVN, EVGN, KALA, BGMS, TRAW, PULM. Left out: ENLV (no annual filing), ENVB (no annual filing), LIANY (no annual filing), LNAI (no annual filing), CUBT (no annual filing). Fiscal periods ending between 2025-08-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (AIM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more AIM signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to AIMand get the insider, 13F, options, and confluence read in one view.